LAUSR

Cystic fibrosis (CF) patient are frequently colonized by multidrug resistant micro-organisms. About 5% and 10% of patients are colonized by Burkholderia cepacia complex (Bcc) and Stenotrophomonas maltophilia respectively, and up to 50% of Pseudomonas aeruginosa isolates are multidrug resistant. 1,2 Ceftazidime-avibactam is a new cephalosporin-inhibitor combination with a potent activity against multidrug-resistant organisms (MDRO) such as KPC and OXA-48 like producing Enterobacteriacae and multidrug resistant P. aeruginosa. However, there is a lack of knowledge of its activity against MDRO recovered in CF, 3 although it has shown an in vitro activity against some strains of Burkholderia spp. This article is protected by copyright. All rights reserved.